Search results
Tiziana eyes orphan drug designation for multiple sclerosis treatment
Proactive Investors· 2 days agoTiziana Life Sciences Ltd (NASDAQ:TLSA) has requested its multiple sclerosis treatment be granted...
9 celebrities with multiple sclerosis who have opened up about the disease
Yahoo Canada Style· 4 days ago“I knew nothing about the disease, to be honest. I fortunately had a doctor who told me right away...
Diagnosing Multiple Sclerosis: 5 Things to Know
Medscape· 6 days agoIn the United States, nearly 1 million people are living with multiple sclerosis (MS), an immune-mediated inflammatory disease that causes demyelination...
This Mother's Day, I'm celebrating the fact that I can bake with my kid again. Not long ago, that...
INSIDER via Yahoo News· 2 days agoReceiving treatment for multiple sclerosis allowed Lindsay Karp (not pictured) to start baking with...
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
WRBL Columbus· 8 hours agoKyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, ...
Ocrevus and interactions: Other drugs, alcohol, and more
Medical News Today· 1 day agoOcrevus (ocrelizumab) is a brand-name injection that’s prescribed for certain forms of multiple ...
Earnings call: Immunic outlines progress and financials for Q1 2024
Investing.com· 6 days agoImmunic, Inc. (NASDAQ: IMUX ) reported a loss in the first quarter of 2024 but showcased progress in...
Sketchy stem-cell treatments in Mexico led to drug-resistant infections
Live Science via Yahoo News· 1 day agoThe injections were reportedly intended to treat the autoimmune disease multiple sclerosis, for...
Immunic advances ‘potentially groundbreaking’ MS therapy vidofludimus calcium during Q1
Proactive Investors· 7 days agoImmunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset,...
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine...
WJTV Jackson· 15 hours agoAs part of the collaboration, PhaseV conducted an independent analysis of NeuroSense's PARADIGM Phase 2b study using a causal ML and predicts a high probability of success in multiple ...